Cargando…

Bortezomib-induced painful neuropathy in patients with multiple myeloma

Neurotoxicity towards the peripheral nervous system which appears clinically in the form of painful neuropathy is an essential dose-limiting factor during the treatment of multiple myeloma. In this review article different forms of this painful neuropathy are presented together with currently availa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bilińska, Małgorzata, Usnarska-Zubkiewicz, Lidia, Pokryszko-Dragan, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934028/ https://www.ncbi.nlm.nih.gov/pubmed/24596530 http://dx.doi.org/10.5114/wo.2013.37214

Ejemplares similares

Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma
por: Allegra, Alessandro, et al.
Publicado: (2021)

P980: THE ROLE OF PLATELET AND ENDOTHELIAL MICROPARTICLES AND DOPPLER ULTRASOUND SCREENING IN THE ASSESSMENT OF THROMBOTIC READINESS IN MULTIPLE MYELOMA AND NON HODGKIN LYMPHOMA, PROSPECTIVE STUDY
por: Olszewska-Szopa, Magdalena, et al.
Publicado: (2023)

Assessment of visual and auditory evoked potentials in multiple sclerosis patients with and without fatigue
por: Pokryszko-Dragan, Anna, et al.
Publicado: (2014)

Sleep disturbances in patients with multiple sclerosis
por: Pokryszko-Dragan, Anna, et al.
Publicado: (2012)

Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients
por: Kulikowska de Nałęcz, Anna, et al.
Publicado: (2021)

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy
por: Dytfeld, Dominik, et al.
Publicado: (2016)

Event-related potentials and cognitive performance in multiple sclerosis patients with fatigue
por: Pokryszko-Dragan, Anna, et al.
Publicado: (2016)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
por: Garcia, M Kay, et al.
Publicado: (2014)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Ascites in the Course of Plasma Cell Myeloma Complicated by AL Amyloidosis
por: Debski, Jakub, et al.
Publicado: (2018)

Preliminary Study on the Role of TMEM39A Gene in Multiple Sclerosis
por: Wagner, Marta, et al.
Publicado: (2017)

Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
por: Grzasko, Norbert, et al.
Publicado: (2021)

Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors
por: Kulikowska de Nałęcz, Anna, et al.
Publicado: (2023)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients
por: Jung, Joo Young, et al.
Publicado: (2014)

Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain
por: Zhi, W. Iris, et al.
Publicado: (2018)

Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy
por: Yamamoto, Shota, et al.
Publicado: (2021)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence
por: Abid, Muhammad Bilal, et al.
Publicado: (2016)

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2017)

Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2013)

Characterization of a rat model of bortezomib‐induced painful neuropathy
por: Duggett, Natalie A, et al.
Publicado: (2017)

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
por: Robak, Paweł, et al.
Publicado: (2020)

Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients
por: Watanabe, T, et al.
Publicado: (2013)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
por: Chen, Wendong, et al.
Publicado: (2016)

Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy
por: Minarik, Jiri, et al.
Publicado: (2015)

Bortezomib-induced aerobic glycolysis contributes to chemotherapy-induced painful peripheral neuropathy
por: Ludman, Taylor, et al.
Publicado: (2019)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data
por: Maschio, Marta, et al.
Publicado: (2018)

Endothelial Function in Patients with Hematologic Malignancies Undergoing High-Dose Chemotherapy Followed by Hematopoietic Stem Cell Transplantation
por: Poręba, Małgorzata, et al.
Publicado: (2015)

Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies
por: Kozalak, Gül, et al.
Publicado: (2023)

Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives
por: Sanz-Solas, Antonio, et al.
Publicado: (2023)

Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report
por: Alali, Yaman, et al.
Publicado: (2021)

Bortezomib a Safe Treatment for Patients with Multiple Myeloma and Cystic Fibrosis
por: Gentilini, Fabiana, et al.
Publicado: (2012)

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
por: Huang, Shang-Yi, et al.
Publicado: (2019)

Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma
por: Bartosińska, Joanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_msjpo3rusn3uls29p275spji1f